10th Annual ECD Medical Symposium Barcelona, Spain
Barcelona Medical Symposium Group Picture 2025
Symposium Summary
Approximately 54 medical professionals from 8 countries attended the Annual ECD Medical Symposium in 2025. Eighteen oral abstracts were presented, along with an additional 8 poster presentations. As an invited speaker, Manel Juan, MD, delivered an invited talk titled “CAR-T-cell Immunoherapies: driving therapies beyond Hematological Cancers, through the Barcelona model.” An evening reception provided time for discussions supporting current and future collaborations among this highly knowledgeable group of physicians and scientists, all interested in learning more about Erdheim-Chester Disease.
Programs with Symposium Agenda
Agenda
| Presenter | Presentation Title & Slides | Video |
|---|---|---|
| Xavier Solanich, Paul Hendrie | Welcome to Barcelona and the 10th Annual Erdheim-Chester Disease International Conference | Watch (1) Watch (2) |
| Manel Juan | CAR-T-cell Immunoherapies: driving therapies beyond Hematological Cancers, through the Barcelona model. | Watch |
| Oshrat Hershkovitz-Rokah | Advanced proteomic profiling for biomarker discovery in Erdheim-Chester Disease | Watch |
| Benjamin Durham | RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition | Watch |
| Julien Haroche | BCL-2 immunohistochemistry expression in patients with histiocytosis | Watch |
| Lindsay Hill | Comparative Genetic Analysis of Primary versus Secondary Histiocytic Sarcoma: A Single Institution Case Series | Watch |
| Carla Isabel Borre | Comparative Efficacy of Frontline Targeted Therapies Versus Chemotherapy in MAPK-Pathway Altered Histiocytic Neoplasms | Watch |
| Francesco Pegoraro | Second cancer in Erdheim-Chester disease | Watch |
| Jerome Razanamahery | Glomeruloid angioma in Erdheim-Chester disease: an atypical skin manifestation associated with elevated VEGF-A | Watch |
| Francesco Catamerò | Treatment Holidays in Patients with Erdheim-Chester Disease Receiving Vemurafenib: A Prospective Pilot Study | Watch |
| Brinda Shukla | Don’t Dish Out Old Therapies: Use of Pegylated-Interferon-Alpha in a case of Erdheim-Chester Disease with congestive heart failure | Watch |
| Eli Diamond | Symptoms, unmet needs, and quality of life in Erdheim-Chester disease: A longitudinal registry-based analysis | Watch |
| Pudis Michal | Diagnostic Impact of 18F-FDG PET/MRI over PET/CT in Histiocytoses: A Prospective Comparative Study | Watch |
| Francesco Pegoraro | Natural history of Erdheim-Chester disease. A preliminary analysis on 1044 patients within the ECDGA network | Watch |
| Mia Poleksic | Erdheim-Chester Disease: Evolving Insights and Improved Survival Over Time | Watch |
| Gaurav Goyal | Real-World Efficacy and Toxicity of MEK Inhibitors in Histiocytic Neoplasms | Watch |
| Jerome Razanamahery | MAPK-kinase mutations and aortic lesions are associated with the distribution of circulating monocytes in histiocytosis | Watch |
| Abdou Malik Da Silva | Deciphering ALK-positive histiocytosis and mimickers using single cell RNAsequencing | Watch |
| Matthew Collin | The clonal origin and evolution of highrisk multisystem histiocytosis in adults | Watch |
| Polyzois Makras | Mapping Erdheim-Chester Disease in Europe through the Core Registry | Watch |
| Jerome Razanamahery | Layers of Complexity: ECD Diagnosis and management in the presence of confounding comorbidities Jerome Razanamahery Dijon University Hospital, Dijon, France Closing Remarks & Student Abstract | Watch |
| Diane Schriner | ECD Global Alliance into the Future | Watch |